© 2022 MJH Life Sciences and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Experts share insight on the evolving treatment armamentarium for myeloproliferative neoplasms.
April 28th 2022
Expert Stephen Oh, MD, PhD, provides a broad overview of the myeloproliferative neoplasms: polycythemia vera, essential thrombocythemia, and myelofibrosis.
Shared insight on making a differential diagnosis of polycythemia vera and properly risk-stratifying patients who present with this disease.
May 5th 2022
Pankit Vachhani, MD, provides a comprehensive overview of approved agents used to manage patients with polycythemia vera.
A brief discussion on the role of ruxolitinib in the management of polycythemia vera, followed by a review of goals of therapy in this setting.
May 12th 2022
Shared insight on the differential diagnosis of myelofibrosis, including advice for identifying primary versus secondary disease.
Reflections on the predominant challenges one may face while making a differential diagnosis of myelofibrosis.
May 19th 2022
Experts focus on how best to risk stratify and stage myelofibrosis using appropriate diagnostic tools and workup.
Expert Pankit Vachhani, MD, breaks down best practices in observation and dictates when it is best to initiated therapy for myelofibrosis.